*Zhu Wenchen, the actual controller of four illegal cases, including false annual report of St Furen, was banned for 10 years

According to the decision on market prohibition issued on October 14 by the website of China Securities Regulatory Commission (No.17 of 2020), it is found that there are illegal facts in the Pharmaceutical Co., Ltd. (hereinafter referred to as “Fu Ren pharmaceutical”, the stock name “*st consoren”, 600781.sh): (/p > < p > Fu Ren pharmaceutical and Furen group, Henan Furen Holding Co., Ltd.) The company (hereinafter referred to as “subsidiary holding”) constitutes a related relationship, and Kaifeng Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as “kaiyao group”) and the subsidiary group and the subsidiary group constitute the related relationship. Since 2015, the company has provided monetary funds to the controlling shareholders, the parent company of the subsidiary group, the subsidiary of the company. The funds provided to the company and the subsidiary holding companies are not recorded in the financial books by the pharmaceutical industry. The non operating occupation of capital of the listed companies by the company has not been disclosed, which leads to false records and significant omissions in the annual reports of 2015 and 2016 disclosed. In 2015, the amount of non operating capital occupied by the group and the subsidiary holding, the balance at the end of the period was RMB 63.8 million, as well as relevant decision-making procedures and reasons for occupation, etc., which led to the major omissions in the annual report of 2015. The above non operating funds are not accounted for, which leads to the false balance of RMB 103million in the end of the monetary fund disclosed in the 2015 annual report of Furen pharmaceutical industry, and the false increase of RMB 63.8 million accounts for 15.17% of the net assets disclosed in the annual report of the current year. In 2016, the company did not disclose the opening amount of 63.8 million yuan, the amount of occurrence of 8.2 million yuan, the ending balance of RMB 72 million, and the relevant decision-making procedures and occupation reasons, which resulted in significant omissions in the annual report of 2016. The above non operating funds are not accounted for, which leads to the false balance of RMB 105million in the end of the monetary fund disclosed in the annual report of Furen pharmaceutical in 2016, and the false increase of RMB 72 million in monetary capital accounts for 16.63% of the net assets disclosed in the annual report of the current year. From April 25, 2016 to December 26, 2017, the company successively disclosed and updated the reorganization report. It intends to issue shares to 14 trading parties such as Fengren group and pay cash to purchase 100% of the total equity of the pharmaceutical development group. It is also called that there is no non operating capital occupation between the subsidiary pharmaceutical industry and the controlling shareholder, actual controller or other related parties. The drug development collection will open the drug collection There is no non operating capital occupation between the group and the Conson group, zhuwenchen or other related parties. The CSRC determined that the major asset restructuring constitutes related transaction and listing by borrowing shell. The drug issuing group of the subject company meets the relevant conditions stipulated in the measures for the administration of IPO and listing. As of December 31st, 2015 and December 31st, 2016, the balance of funds provided by the development pharmaceutical group and its subsidiaries to the subsidiary of the subsidiary group and subsidiary of the pharmaceutical development group and the subsidiary of the subsidiary group was 350million yuan and 504million yuan respectively. The above transactions were not recorded in the financial books by the pharmaceutical development group, which led to the false balance of monetary funds in the financial statements of the Pharmaceutical Group disclosed in the restructuring report. The above-mentioned illegal facts and the illegal facts have also resulted in false records in the balance of monetary funds in the financial statements of preparation for the pharmaceutical industry of Conson pharmaceutical disclosed in the reorganization report. In 2015 and 2016, the monetary funds increased by 413million yuan and 576million yuan respectively, accounting for 12.95% and 14.79% of the net assets at the end of each year. Most of the above-mentioned occupied funds have not been returned since the CSRC accepted and approved. Therefore, there are false records in the statement of non operating capital occupation in the reorganization report. The CSRC believes that the act of the company disclosing false record reorganization report violates the measures for the management of major assets reorganization of listed companies (Order No. 109 of CSRC on October 23, 2014, September 8th, 2016) Article 4 of the decree of the CSRC and Article 63 of the securities law of 2005 constitute the acts mentioned in Article 55, paragraph 1, of the measures for the administration of major assets reorganization of listed companies and the acts mentioned in Article 193, paragraph 1, of the securities law of 2005. The report of false record reorganization submitted by the pharmaceutical industry of consoren to the CSRC for examination and approval constitutes the acts described in Article 54 of the measures for the administration of major assets reorganization of listed companies and the acts described in Article 193, paragraph 2, of the securities law of 2005. According to Article 26 of the measures for the management of major assets reorganization of listed companies, zhuwenchen signed the previous reorganization reports to ensure the authenticity, accuracy and integrity of the contents of the reorganization report. The group is the controlling shareholder of the pharmaceutical industry and the development group. In order to realize the overall listing of pharmaceutical assets, the company plans, organizes and implements the injection of the pharmaceutical development group into the pharmaceutical industry of Furen, which is a major asset reorganization under the same control. In 2015 and 2016, the company occupied the funds of subsidiary companies of the pharmaceutical development group in a large scale, and did not provide relevant information to the pharmaceutical industry in the restructuring. As the other party of the transaction, the company publicly promises to ensure the authenticity, accuracy and integrity of the information provided. The CSRC believes that the above-mentioned behaviors of Fengren group violate the provisions of Article 4 of the measures for the management of major assets reorganization of listed companies, and constitute the behaviors described in Article 55, paragraph 2, of the measures for the management of major assets reorganization of listed companies. According to the provisions of Article 55, paragraph 2, of the measures for the administration of major assets reorganization of listed companies, the punishment shall be imposed in accordance with Article 193 of the securities law of 2005, and zhuwenchen shall be the person in charge directly in charge. In 2017 and 2018, there are false records and major omissions in the annual reports of consortia pharmaceutical industry. In 2018, the related guarantee was not disclosed in time

< p > in 2017, the pharmaceutical industry of Furen pharmaceutical incorporated the pharmaceutical development group into the consolidated report. The funds provided by the company and the development group to the subsidiary group and the subsidiary holding company in the previous years have not been returned in 2017 and 2018, and new occupation has occurred. The company has not accounted for the relevant capital occupation, nor disclosed the non operating occupation of the funds of the listed companies by the company, which led to the annual reports of 2017 and 2018 disclosed There are false records and major omissions. In 2017, the company did not disclose the opening amount of RMB 576million, the amount of which was RMB 109 million, the balance at the end of the period was RMB 467 million, and the relevant decision-making procedures and reasons for occupation, which resulted in significant omissions in the 2017 annual report. The above non operating funds are not accounted for, which leads to the false balance of RMB 1.289 billion of monetary capital disclosed in the 2017 annual report of Furen pharmaceutical industry, and the false increase of Monetary Fund of RMB 467 million accounts for 10.02% of the net assets disclosed in the annual report of the current year. In 2018, the company did not disclose the opening amount of RMB 467 million, the amount of occurrence of 87million yuan, the ending balance of RMB 1.337 billion, and the relevant decision-making procedures and occupation reasons, which resulted in significant omissions in the 2018 annual report. The above non operating funds are not accounted for, which leads to the false balance of RMB 1.656 billion of monetary capital disclosed in the 2018 annual report of Furen pharmaceutical industry, and the false increase of RMB 1.337 billion accounts for 24.45% of the net assets disclosed in the annual report of the current year. In addition, in 2018, Furen pharmaceutical provided four guarantees for loan from Conson group and zhuwenchen, involving a total contract amount of 140million yuan, and the outstanding amount as of December 31st, 2018 was RMB 72 million. The company did not disclose the matter in time or in the 2018 annual report, which led to significant omissions in the relevant annual report. The CSRC believes that the financial capital increased in the annual report of Furen pharmaceutical from 2015 to 2018, the occupation of non operating funds of the controlling shareholders and their related parties, and the guarantee of related parties in the 2018 annual report has not been disclosed, which leads to the false records and major omissions in the periodic report, which violates Article 63 of the securities law of 2005. The public offering of securities publicly is in violation of Article 63 of the securities law of 2005 The information disclosure content and format standard of the Company No. 2 – Contents and forms of annual report (CSRC announcement [2015] No. 24, CSRC announcement [2016] No. 31, CSRC announcement [2017] No. 17), Article 31, paragraph 1, Article 40, item 4 and Article 66 (6) of securities law of 2005 constitute Article 193, Article 193, Article 1, Article 6, item 6 of Securities Law of 2005 The act described in paragraph. Zhuwenchen signed written confirmation opinions on the annual report from 2015 to 2018 to ensure that the annual report from 2015 to 2018 is true, accurate and complete and is the person in charge directly in charge. In 2018, the company failed to disclose the related party guarantee in time, and violated the provisions of Circular on regulating the external guarantee of listed companies (zjf [2005] No. 120) (V) and Article 67 (2) item 12 of Securities Law of 2005, which constitutes the behavior described in Article 193, paragraph 1, of the securities law of 2005. Zhuwenchen, chairman of the pharmaceutical industry of Furen, is the person in charge directly. It is judged by the CSRC that as the actual controller, chairman and general manager of the pharmaceutical industry of Furen, zhuwenchen, as the actual controller of the group, decides and arranges the capital of the subsidiary group and the subsidiary group to occupy the capital of the pharmaceutical industry and the development group. He knows not only that the subsidiary pharmaceutical industry is occupied by the subsidiary group and the subsidiary Ren group, but also knows that the subject asset development group is also known to be occupied by the subsidiary benevolent group and the subsidiary Ren holding In the case of capital occupied by the subsidiary group and the company, it still signs and promises to ensure the authenticity, accuracy and completeness of the reorganization report and regular report, and bears the main responsibility in the violation of the guarantee, which seriously damages the interests of investors, and the violation of the law is serious. According to the provisions of article 233 of Securities Law 2005 and Article 3, paragraph 1 and Article 5 of the provisions on the prohibition of entry into the securities market (Order No. 115 of CSRC), the CSRC decided to take 10-year securities market ban measures against zhuwenchen. Since the date of announcement and decision, it shall not continue to engage in securities business or act as the original listed company in the original institution during the period of prohibition The directors, supervisors and senior managers of non listed public companies shall not engage in securities business or other positions as directors, supervisors and senior managers of other listed companies or non listed public companies in any other institutions. It was found by the reporter of China economic network that * ST Conson was founded on August 13, 1993, with a registered capital of RMB 627million, and was listed on the Shanghai Stock Exchange on December 18th, 1996. Jiang Zhihua is now the legal representative and chairman of the board of directors. As of August 20, 2020, the company is the largest shareholder, holding 228million shares, with a shareholding ratio of 36.36%. Founded on January 22997, the company has a registered capital of RMB 400million. Zhuwenchen, the legal representative, the controller and the chairman of the board, is a wholly-owned subsidiary of the company. Zhuwenchen is the first major shareholder and actual controller of the wholly-owned subsidiary of the subsidiary of Fengren technology holding (Beijing) Group Co., Ltd., with a shareholding ratio of 97.37%. Henan Furen Holding Co., Ltd. was renamed as “Henan Furen Holding Group Co., Ltd.” in May 2018, it was renamed as “Fengren technology holding (Beijing) Group Co., Ltd.” in November 2018. Founded on September 26, 2003, Kaifeng Pharmaceutical (Group) Co., Ltd. has registered capital of 2.05